Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 added and v3.4.2 removed; this is a minor versioning update with no changes to study data or page behavior.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded 'Oropharynx cancer' as a related condition and a new 'Genetic and Rare Diseases Information Center' resource under Resources.SummaryDifference0.1%

- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1, and removed the government funding status notice about potential delays.SummaryDifference0.3%

- Check41 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and potential delays, with status links; updated the site version to v3.4.1 (from v3.4.0).SummaryDifference0.3%

- Check48 days agoChange DetectedAdded a Show glossary option and updated several labels and version text, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the older phrasing 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 appears replacing v3.3.3; no substantive content or functional changes to the study details are evident in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.